Lomitapide regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Oct. 17 to discuss an NDA from Aegerion for lomitapide to treat homozygous familial hypercholesterolemia (hoFH). The small mole...